Isabl
Cancer tests based on whole genome and transcriptome data.
Isabl has developed software that can analyze the entire genome of cancer patients. Today, when people get cancer, they get a genetic test of their tumor that analyzes only a few possible mutations. With Isabl, you run the tumor through an Illumina sequencer and get the whole genome, then our software is able to analyze all the mutations. Our breakthrough technology provides unprecedented clarity into tumor biology to aid treatment planning. This opens up opportunities for precision diagnostics, disease surveillance and biomarker discovery.
- Website
- isabl.io
- City
- New York City
- Country
- United States
- YC batch
- Winter 2020
- Team
- 5 people
- Stage
- Early stage
- AI-native
- No
More Health & bio in New York City
Ro$5bn
Health technology. Valued at $5bn (March 2021).
Noom$3.7bn
Healthcare. Valued at $3.7bn (May 2021).
Headway$2.3bn
Healthcare. Valued at $2.3bn (July 2024).
Sword Health$2bn
Health. Valued at $2bn (November 2021).
H1
Connecting stakeholders across the healthcare ecosystem.
Opentrons
We make robots for biologists.
Claim this profile
Free and instant: prove you run isabl.io and edit the profile yourself.
- Your logo, office address and founder photos
- The ✓ Verified mark next to Isabl across the site
- Open roles listed on the Hiring board
- A followed link back to your website
A rank card with Isabl's standing on Labspie, or a simple badge. Both link to this profile and update themselves.
